Research on GLP-1 medications, including semaglutide and tirzepatide, is examining whether the drugs may affect health conditions beyond obesity. The evidence described in the source ranges from clinical-trial results to observational findings, and researchers have not established that every potential benefit is independent of weight loss.
A study published in The Lancet found that semaglutide lowered the risk of heart attack, stroke and cardiovascular death among people with existing cardiovascular disease who also had overweight or obesity. The source says the results appeared across different body weights and were not fully accounted for by weight loss. It does not provide the study’s participant count or the size of the risk reduction.
Joint pain is another area under investigation. In the STEP 9 clinical trial, published in the New England Journal of Medicine, adults with obesity who received semaglutide had less knee osteoarthritis pain and better physical function. The source notes that researchers are still working to distinguish the effects of weight loss from any other effects of GLP-1 medicines.
The source also describes potential kidney benefits. These drugs may influence kidney health through changes in blood sugar, blood pressure and inflammation. In the FLOW trial, semaglutide lowered the risk of major kidney complications and cardiovascular death by 24% among people with type 2 diabetes and chronic kidney disease, according to the report. The source does not give further details about the trial’s duration or participant numbers.
For liver disease, researchers are studying GLP-1 medicines in patients with metabolic dysfunction-associated steatohepatitis, or MASH, a condition involving liver inflammation and cell damage. A clinical trial reported in the New England Journal of Medicine found improvements in liver tissue among patients taking semaglutide, including reduced inflammation and scarring. MASH resolved without worsening liver fibrosis in 62.9% of those receiving semaglutide, compared with 34.3% of those given a placebo. The extent to which the results reflect weight loss remains an open question.
Respiratory findings are less settled. Research presented at the European Respiratory Society Congress associated GLP-1 medication use with fewer asthma attacks and chronic obstructive pulmonary disease flare-ups. The source characterizes this as a real-world association and says further research is needed to determine whether the medicines directly improve respiratory health. An association alone does not establish that the drugs caused the difference.
Possible effects on mental health and addiction are also being explored. The source notes that GLP-1 receptors are present in brain areas associated with appetite, emotion, motivation and reward. An observational study posted on medRxiv linked semaglutide use with lower rates of substance-related and mood disorders. That research has not been peer-reviewed, and it does not show that semaglutide caused the lower rates.
In dermatology, a JAMA Dermatology clinical trial found that adding tirzepatide to an existing psoriasis treatment improved skin clearance in adults with moderate to severe psoriasis and overweight or obesity. The report does not specify how large the improvement was or whether it would apply to patients outside the group studied.
Overall, the findings cover several different medicines and conditions, and their strength varies. The source says effects can differ by medication and individual, while researchers continue to study whether observed changes result from weight loss, reduced inflammation or a combination. It advises patients to discuss possible risks and benefits with a health care provider.
